The US Food and Drug Administration’s Janet Woodcock is under investigation for an alleged conflict of interest involving two generic drugmakers and approval of their drugs. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/woodcock_investigated_for_conflict_of_interest_983825The Biotechnology Industry Organisation is asking the US Government for a financial stimulus for small biotech companies that are struggling during the credit crunch. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/biotech_asks_us_government_for_help_986188Sanofi-Aventis has created the third largest generics company in Europe after re-branding its generic operations under the name Zentiva. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/sanofi-aventis_re-brands_generics_business_as_zentiva_979313Apotex has been unsuccessful in its bid to secure the rights to market a generic version of Sanofi-Aventis’ blockbuster blood thinner Plavix (clopidogrel) in Canada. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/apotex_loses_canadian_plavix_patent_case_986434Genentech and OSI Pharmaceuticals have announced the combination treatment of Avastin (bevacizumab) with Tarceva (erlotinib) has not shown to improve survival in a Phase III study. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/avastintarceva_combo_does_not_improve_survival_986661Sun Pharma has bought Ranbaxy for $4 billion to create the world’s fifth-biggest generic drugmaker. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/sun_buys_ranbaxy_for_$4_billion_1001783The UK-based Wellcome Trust has launched the new evergreen investment company Syncona Partners to provide capital to life science start-ups. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/wellcome_trust_launches_investment_arm_1004167As many as 84% of Americans blame the pharmaceutical industry for the country’s healthcare woes, a new survey has found. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/pharma_partly_to_blame_for_healthcare_woes_983672Amgen has received both good and bad news regarding the recommended approval of its eagerly anticipated osteoporosis drug Prolia (denosumab) in the USA. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/amgen_gets_mixed_news_over_denosumab_983821The UK’s Diamond Light Source in Oxfordshire is to become the first and only place in Europe to analyse serious viruses, the results of which will be used to create new therapies to treat viral disease. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/new_uk_facility_to_analyse_serious_viruses_1004462
